Flow Induced
Dispersion Analysis

Over 10 Essential Biophysical Parameters Delivered by 1 Technology in 1 Assay

Make right decisions, earlier.
Loxo Lilly
Modena
Agilent
Novartis
GSK
Beam
Lilly
Sanofi
Astra Zeneca
Novo Nordisk
Bristol Myers Sqibb
Merck
UT Southwestern
EPFL
Phy6bio
VIB VUB
University of Copenhagen
University Jena
Universiteit Utrecht
Uni Greiburg
IGBMC
Ensoma
LMU
Spolight
Peak
NW
Institut
Eurofins
DTU
Diamond
Aarchus
Francis
Monte Rosa
MIP Discovery

Answer all biophysics questions with a single technology.

Answer all biophysics questions with a single technology.

1/3

Quality
& Quantity

Kinetics

Affinity

2/3

Completing the picture with
in-solution biophysics.

3/3

Introducing Fida Neo

In-solution
No non-specific binding issues. Embrace the fluid characteristics akin to biological systems.
Absolute measurements
Directly measure the size (Rh) of the molecule or construct of interest.
Quality Control Module
8 Quality Control measurements with every sample tested.
Label-free or labelled
Multiple detector wavelengths available.
Any sample matrix
Unpurified and with no buffer constraints on detergent, pH, ionic strength etc.

FIDA in Numbers

8
Quality Control Parameters
1 day
To first data
40 nL
Analyte (down to 4 μL)
3x
Temperature Control
9
Big Pharma companies already have one
2x50/2x96
Plates - Fully Automated
100mM - 10pM
Binding affinities
3
Wavelengths
available: 
480 nm, 640 nm or 280 nm LED
0.5 - 500nm
Size Range

This methodology is very sensitive and useful for assessing binding in a quantitative manner using small amounts of auto-fluorescent proteins. Using this method, we can observe clear changes in apparent hydrodynamic radius (Rh) and in fluorescence signal of EYA1 as a function of increasing concentrations of peptides or of small molecules

Dana Farber Institute
CANCER INSTITUTE

''Fida  Instrument provides a ''ruler'' to measure the length of fibrils''

Stefan Rüdiger Ph.D.
Professor of Protein Chemistry of Disease; Head of Department of Chemistry

''The FIDA is very effective for screening small molecules for solubility and interactions with protein targets. A major advantage has been its ability to clearly show drug binding to difficult-to-work-with targets such as intrinsically disordered proteins and amyloids''

Dr. Alexander Taylor
Research Fellow in Biochemistry/Biophysics

I would say that this instrument is quite useful for core facilities at KI or for Swedish research community in general:

  1. it was possible to measure unlabeled membrane proteins and soluble proteins at low concentrations in small volumes very fast (~6 minutes per measurement).
  2. I also like the temperature control and the autosampler which allowed us to run a lot of samples overnight.
  3. I would say that there is a lot of potential to perform other assays as well, such as the Kd determinations etc. (For this, I use ITC which is quite time-consuming and requires a lot of protein).
  4. In addition, the software and user interface for sample runs and data analysis is quite straightforward and intuitive to use.
Postdoctoral Researcher

"What we value about FIDA is the amount of information we can get from a tiny amount of protein in a single QC run. FIDA technology enables us to understand our proteins better - particularly when they behave in unexpected ways. We chose FIDA because it gives us that vital first result quickly - we don't waste our time optimising an assay that isn't going to work."

Duncan Smith
Lead Scientist

"I am convinced. I have never before been able to detect the ternary construct formation of my construct directly in cell lysate – it took less than two hours."

Thomas Smith
Associate Director, Chemical Biology & Therapeutics

"The Fida 1’s unique capability for measuring binding Kd from weak mM level to strong pM level really enhances our bioanalytical capabilities."

Sherry Zhu
Senior Scientist

"FIDA is an in-solution technique, and thus an ideal binding assay for structurally diverse bsAbs because the analysis does not rely on potentially obstructive surface immobilization and hence it is able to perform characterizations that are unbiased by bsAb format and spatial orientation of the binding domains."

Andreas V. Madsen
PhD Student

"After thorough comparisons, it was clear that the Fida 1, amongst others, presents unique opportunities in analysis of membrane proteins, which is essential to us."

Svend Kjæer
STP Deputy

''The Fida 1 system offers a new approach to detergent screening that has significant advantages allowing essential data to be obtained faster using less material (…) this work presents a new approach to characterize membrane proteins that allows users to reducing costs and time as well as to analyze protein expressed at low levels in a short time thus overcoming any stability issues.''

Isabel Moraes
Principal Research Scientist

"I like the ease of use and the straightforward data analysis and, that experiments can be performed in any type of buffers. We get data, where no other biophysical methods worked before."

Cathrine Birck
Head of Integrated Structural Biology Platform

"The method is easy to setup in any standard laboratory and can be adopted for a high throughput (HTTP) screening, which enabled mechanistic studies of RNA nuclease interactions, as well as efficient guide RNA lead discovery (…) Fida 1 offers straightforward assay development, walk away automation, absolute measurement and ultra low sample consumption."

Denny Truong
Principal Research Associate

"FIDA provides in-depth assessment of activity combined with local and global protein structural changes by measuring the overall hydrodynamic radius of the protein with minimal sample consumption. In addition, it is possible to measure the affinity constant for the analyzed interaction."

Dr. Melanie Hug
Research Associate

"The beauty of Fida 1 is that it allows us to conduct a lot of biophysical measurements in one system using a small amount of reagent and a rapid read-out time which is important for our projects and to our customers. (…) Providing a high-quality, protein characterisation QC package is certainly extending and future proofing our capabilities in biophysical characterisation of the proteins we produce."

Mark Abbott
Managing Director

"The Fida 1 has allowed us to assess the performance of MIPs with a much higher throughput than was previously possible on other platforms. MIPs can be developed in as little as 8 weeks, which is a significant improvement on antibodies, and now they can be fully characterized at an accelerated pace too."

Alan Thomson
CEO

"Fida 1 can be used for full characterization of ternary complex formation for targeted protein degradation. The Fida 1 platform only consumes 39 nL of sample for one measurement and thus allows elaborate condition screening using very small amounts of sample material."

Roman Agafonov
Associate Director of Biochemistry, Biophysics & Structural Biology

"The Fida1 is a very user-friendly system. With the Fida software we can quickly design new methods, set up experiments, and analyze data. By far this is a great instrument and technology that has allowed us to run binding assays for LNP in solution and with flexibility to run in any complex media which we were unable to do using traditional binding methods that required ligand immobilization. The FidaBio customer service is amazing, they are very knowledgeable and responsive whenever I run into issues and need assistance. I highly recommend this instrument for LNP or any other nanoparticle characterization. The system and technology are versatile with applications beyond nanoparticles and is a must in the biophysical tool kit."

Biophysical Analytical Department
Senior Scientist, Analytical Development

"Eventually, with FIDA, we managed to characterise our LNPs. And it was done in less than 2 days. We had for a long time been struggling with SPR."

Chemical Biology and Therapeutics
Associate Director

"We had been looking for ways of quantifying our exosomes, and tested many platform, without success. In less than 2 days FIDA had developed an assay and shown trustworthy quantifications directly in fermentation broth"

Rane Harrison
Director, Analytical Development